BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Li X, Tian Y, Tu MJ, Ho PY, Batra N, Yu AM. Bioengineered miR-27b-3p and miR-328-3p modulate drug metabolism and disposition via the regulation of target ADME gene expression. Acta Pharm Sin B 2019;9:639-47. [PMID: 31193825 DOI: 10.1016/j.apsb.2018.12.002] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 10.7] [Reference Citation Analysis]
Number Citing Articles
1 Seo HA, Moeng S, Sim S, Kuh HJ, Choi SY, Park JK. MicroRNA-Based Combinatorial Cancer Therapy: Effects of MicroRNAs on the Efficacy of Anti-Cancer Therapies. Cells 2019;9:E29. [PMID: 31861937 DOI: 10.3390/cells9010029] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 6.3] [Reference Citation Analysis]
2 He B, Zhao Z, Cai Q, Zhang Y, Zhang P, Shi S, Xie H, Peng X, Yin W, Tao Y, Wang X. miRNA-based biomarkers, therapies, and resistance in Cancer. Int J Biol Sci 2020;16:2628-47. [PMID: 32792861 DOI: 10.7150/ijbs.47203] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
3 Chen HY, Lu J, Wang ZK, Yang J, Ling X, Zhu P, Zheng SY. Hsa-miR-199a-5p Protect Cell Injury in Hypoxia Induces Myocardial Cells Via Targeting HIF1α. Mol Biotechnol 2021. [PMID: 34843094 DOI: 10.1007/s12033-021-00423-7] [Reference Citation Analysis]
4 Wang Z, Yan J, Yang F, Wang D, Lu Y, Liu L. MicroRNA-326 prevents sepsis-induced acute lung injury via targeting TLR4. Free Radical Research 2020;54:408-18. [DOI: 10.1080/10715762.2020.1781847] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
5 Yu AM, Tu MJ. Deliver the promise: RNAs as a new class of molecular entities for therapy and vaccination. Pharmacol Ther 2021;:107967. [PMID: 34403681 DOI: 10.1016/j.pharmthera.2021.107967] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Guo Q, Li C, Zhou W, Chen X, Zhang Y, Lu Y, Zhang Y, Chen Q, Liang D, Sun T, Jiang C. GLUT1-mediated effective anti-miRNA21 pompon for cancer therapy. Acta Pharm Sin B 2019;9:832-42. [PMID: 31384542 DOI: 10.1016/j.apsb.2019.01.012] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
7 Yin J, Li F, Zhou Y, Mou M, Lu Y, Chen K, Xue J, Luo Y, Fu J, He X, Gao J, Zeng S, Yu L, Zhu F. INTEDE: interactome of drug-metabolizing enzymes. Nucleic Acids Res 2021;49:D1233-43. [PMID: 33045737 DOI: 10.1093/nar/gkaa755] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 7.0] [Reference Citation Analysis]
8 Petrek H, Yan Ho P, Batra N, Tu MJ, Zhang Q, Qiu JX, Yu AM. Single bioengineered ncRNA molecule for dual-targeting toward the control of non-small cell lung cancer patient-derived xenograft tumor growth. Biochem Pharmacol 2021;189:114392. [PMID: 33359565 DOI: 10.1016/j.bcp.2020.114392] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
9 Li W, Hou G, Lv J, Lin F, Song G, Li R. MicroRNA-30d-5p ameliorates lipopolysaccharide-induced acute lung injury via activating AMPKα. Immunopharmacol Immunotoxicol 2021;43:431-42. [PMID: 34157933 DOI: 10.1080/08923973.2021.1933517] [Reference Citation Analysis]
10 Yi W, Tu MJ, Liu Z, Zhang C, Batra N, Yu AX, Yu AM. Bioengineered miR-328-3p modulates GLUT1-mediated glucose uptake and metabolism to exert synergistic antiproliferative effects with chemotherapeutics. Acta Pharm Sin B 2020;10:159-70. [PMID: 31993313 DOI: 10.1016/j.apsb.2019.11.001] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 16.0] [Reference Citation Analysis]
11 Yu AM, Choi YH, Tu MJ. RNA Drugs and RNA Targets for Small Molecules: Principles, Progress, and Challenges. Pharmacol Rev 2020;72:862-98. [PMID: 32929000 DOI: 10.1124/pr.120.019554] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 15.5] [Reference Citation Analysis]
12 Deng L, Petrek H, Tu MJ, Batra N, Yu AX, Yu AM. Bioengineered miR-124-3p prodrug selectively alters the proteome of human carcinoma cells to control multiple cellular components and lung metastasis in vivo. Acta Pharm Sin B 2021;11:3950-65. [PMID: 35024318 DOI: 10.1016/j.apsb.2021.07.027] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
13 Chen YF, Hu F, Wang XG, Tang Z, Tang HX, Xu M. MicroRNA-23a-5p Is Involved in the Regulation of Lipopolysaccharide-Induced Acute Lung Injury by Targeting HSP20/ASK1. Oxid Med Cell Longev 2021;2021:9942557. [PMID: 34422215 DOI: 10.1155/2021/9942557] [Reference Citation Analysis]
14 Hashemi A, Gorji-Bahri G. MicroRNA: Promising Roles in Cancer Therapy. Curr Pharm Biotechnol 2020;21:1186-203. [PMID: 32310047 DOI: 10.2174/1389201021666200420101613] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
15 Yin C, Tian Y, Yu Y, Yang C, Su P, Zhao Y, Wang X, Zhang K, Pei J, Li D, Chen Z, Zhang Y, Miao Z, Qian A. miR-129-5p Inhibits Bone Formation Through TCF4. Front Cell Dev Biol 2020;8:600641. [PMID: 33240893 DOI: 10.3389/fcell.2020.600641] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
16 Chen L, Manautou JE, Rasmussen TP, Zhong XB. Development of precision medicine approaches based on inter-individual variability of BCRP/ABCG2. Acta Pharm Sin B 2019;9:659-74. [PMID: 31384528 DOI: 10.1016/j.apsb.2019.01.007] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 7.7] [Reference Citation Analysis]
17 Yi WR, Tu MJ, Yu AX, Lin J, Yu AM. Bioengineered miR-34a modulates mitochondrial inner membrane protein 17 like 2 (MPV17L2) expression toward the control of cancer cell mitochondrial functions. Bioengineered 2022;13:12489-503. [PMID: 35579419 DOI: 10.1080/21655979.2022.2076399] [Reference Citation Analysis]
18 Ning B, Yu D, Yu AM. Advances and challenges in studying noncoding RNA regulation of drug metabolism and development of RNA therapeutics. Biochem Pharmacol 2019;169:113638. [PMID: 31518552 DOI: 10.1016/j.bcp.2019.113638] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
19 Wang J, Yu L, Jiang H, Zheng X, Zeng S. Epigenetic Regulation of Differentially Expressed Drug-Metabolizing Enzymes in Cancer. Drug Metab Dispos 2020;48:759-68. [PMID: 32601104 DOI: 10.1124/dmd.120.000008] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
20 Petrek H, Batra N, Ho PY, Tu MJ, Yu AM. Bioengineering of a single long noncoding RNA molecule that carries multiple small RNAs. Appl Microbiol Biotechnol 2019;103:6107-17. [PMID: 31187211 DOI: 10.1007/s00253-019-09934-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
21 Zhai K, Duan H, Wang W, Zhao S, Khan GJ, Wang M, Zhang Y, Thakur K, Fang X, Wu C, Xiao J, Wei Z. Ginsenoside Rg1 ameliorates blood-brain barrier disruption and traumatic brain injury via attenuating macrophages derived exosomes miR-21 release. Acta Pharm Sin B 2021;11:3493-507. [PMID: 34900532 DOI: 10.1016/j.apsb.2021.03.032] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 12.0] [Reference Citation Analysis]
22 Li Y, Meng Q, Yang M, Liu D, Hou X, Tang L, Wang X, Lyu Y, Chen X, Liu K, Yu AM, Zuo Z, Bi H. Current trends in drug metabolism and pharmacokinetics. Acta Pharm Sin B 2019;9:1113-44. [PMID: 31867160 DOI: 10.1016/j.apsb.2019.10.001] [Cited by in Crossref: 58] [Cited by in F6Publishing: 45] [Article Influence: 19.3] [Reference Citation Analysis]
23 Zhang HF, Zhu LL, Yang XB, Gao N, Fang Y, Wen Q, Qiao HL. Variation in the expression of cytochrome P450-related miRNAs and transcriptional factors in human livers: Correlation with cytochrome P450 gene phenotypes. Toxicol Appl Pharmacol 2021;412:115389. [PMID: 33385404 DOI: 10.1016/j.taap.2020.115389] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
24 Yin X, Liao Y, Xiong W, Zhang Y, Zhou Y, Yang Y. Hypoxia-induced lncRNA ANRIL promotes cisplatin resistance in retinoblastoma cells through regulating ABCG2 expression. Clin Exp Pharmacol Physiol 2020;47:1049-57. [PMID: 32173903 DOI: 10.1111/1440-1681.13279] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
25 Yan Z, Wang D, An C, Xu H, Zhao Q, Shi Y, Song N, Deng B, Guo X, Rao J, Cheng L, Zhang B, Mou L, Yang W, Jiang X, Xie J. The antimicrobial peptide YD attenuates inflammation via miR-155 targeting CASP12 during liver fibrosis. Acta Pharm Sin B 2021;11:100-11. [PMID: 33532183 DOI: 10.1016/j.apsb.2020.07.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
26 Zheng H, Shi M, Chi Z, Wang H, Wang H, Xu D. Dysregulated pseudogene BNIP3P1 inhibited cell proliferation and promoted cell apoptosis in preeclampsia by acting as a competing endogenous RNA for BNIP3. Environmental Toxicology. [DOI: 10.1002/tox.23159] [Reference Citation Analysis]
27 Chen Y, Liu C, Zhou P, Li J, Zhao X, Wang Y, Chen R, Song L, Zhao H, Yan H. Liraglutide reduces coronary endothelial cells no-reflow damage through activating MAPK/ERK signaling pathway. Journal of Receptors and Signal Transduction. [DOI: 10.1080/10799893.2020.1833921] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
28 Zhang H, Tian Y, Liang D, Fu Q, Jia L, Wu D, Zhu X. The Effects of Inhibition of MicroRNA-375 in a Mouse Model of Doxorubicin-Induced Cardiac Toxicity. Med Sci Monit 2020;26:e920557. [PMID: 32186283 DOI: 10.12659/MSM.920557] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
29 Li DF, Yuan Y, Tu MJ, Hu X, Li YZ, Yi WR, Li PC, Zhao Y, Cheng Z, Yu AM, Jian C, Yu AX. The Optimal Outcome of Suppressing Ewing Sarcoma Growth in vivo With Biocompatible Bioengineered miR-34a-5p Prodrug. Front Oncol 2020;10:222. [PMID: 32161722 DOI: 10.3389/fonc.2020.00222] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
30 He X, Sun H, Jiang Q, Chai Y, Li X, Wang Z, Zhu B, You S, Li B, Hao J, Xin S. Hsa-miR-4277 Decelerates the Metabolism or Clearance of Sorafenib in HCC Cells and Enhances the Sensitivity of HCC Cells to Sorafenib by Targeting cyp3a4. Front Oncol 2021;11:735447. [PMID: 34381736 DOI: 10.3389/fonc.2021.735447] [Reference Citation Analysis]
31 Jiang WL, Zhao KC, Yuan W, Zhou F, Song HY, Liu GL, Huang J, Zou JJ, Zhao B, Xie SP. MicroRNA-31-5p Exacerbates Lipopolysaccharide-Induced Acute Lung Injury via Inactivating Cab39/AMPKα Pathway. Oxid Med Cell Longev 2020;2020:8822361. [PMID: 33101593 DOI: 10.1155/2020/8822361] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
32 Yin J, Sun W, Li F, Hong J, Li X, Zhou Y, Lu Y, Liu M, Zhang X, Chen N, Jin X, Xue J, Zeng S, Yu L, Zhu F. VARIDT 1.0: variability of drug transporter database. Nucleic Acids Res 2020;48:D1042-50. [PMID: 31495872 DOI: 10.1093/nar/gkz779] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 18.5] [Reference Citation Analysis]
33 Zhang X, Chen Q, Song H, Jiang W, Xie S, Huang J, Kang G. MicroRNA‑375 prevents TGF‑β‑dependent transdifferentiation of lung fibroblasts via the MAP2K6/P38 pathway. Mol Med Rep 2020;22:1803-10. [PMID: 32582987 DOI: 10.3892/mmr.2020.11261] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]